TP53 and triple-negative breast carcinoma: Interestingly, p53 pathway is mutated in >90% of triple negative breast cancers and both Chk1 and GSK3-β inhibitors have been shown to affect cell growth of cell lines derived from such tumours [24,34,35,37,38].